Urine-based antigen detection assay for diagnosis of visceral leishmaniasis using monoclonal antibodies specific for six protein biomarkers of Leishmania infantum / Leishmania donovani
Open Access
- 23 April 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 14 (4) , e0008246
Abstract
The development of an accurate protein-based antigen detection assay for diagnosis of active visceral leishmaniasis (VL) would represent a major clinical advance. VL is a serious and fatal disease caused by the parasites Leishmania infantum and Leishmania donovani. The gold standard confirmatory diagnostic test for VL is the demonstration of parasites or their DNA from aspirates from spleen, lymph node, and bone marrow or from blood buffy coats (DNA tests). Here we describe the production and use of monoclonal antibodies (mAbs) for the development of a sensitive and specific antigen detection capture ELISA for VL diagnosis. This test simultaneously detects six leishmania protein biomarkers that we have previously described (Li-isd1, Li-txn1, Li-ntf2, Ld-mao1, Ld-ppi1 and Ld-mad1). The initial clinical validation of this new mAb-based multiplexed capture ELISA showed a sensitivity of ≥93%. The test was negative with 35 urine samples from healthy control subjects as well as with 30 patients with confirmed non-VL tropical diseases (cutaneous leishmaniasis, n = 6; Chagas disease, n = 6; schistosomiasis, n = 6; and tuberculosis, n = 12). These results strongly support the possible utility of this mAb-based multiplexed capture ELISA as a promising diagnostic test for active VL as well as for monitoring the treatment efficacy of this disease. The test is ready for upscaling and validation for clinical use. Visceral leishmaniasis (VL) or kala-azar is a systemic parasitic disease that is endemic in 75 countries with more than 500 million people at risk of infection. VL is caused primarily by the parasites known as Leishmania infantum and Leishmania donovani. It is estimated that VL affects 50,000–90,000 people each year, with 90% of the cases occurring in India, Kenya, Somalia, Sudan, South Sudan and Brazil. VL is a fatal disease if not treated. Laboratory diagnosis of this disease can be performed using several different approaches. However, there is still a need for a simple, non-expensive, sensitive and specific test that can be used not only for the accurate diagnosis of this serious disease but also to monitor the efficacy of its treatment. Here we describe a new test that can circumvent most of the drawbacks of existing approaches. This new test detects six leishmanial proteins or biomarkers that are eliminated in the urine of patients with VL. The test is a conventional ELISA assembled with monoclonal antibodies (mAbs) specific for each of the six different biomarkers and it is performed in urine samples of suspected patients. An initial clinical validation demonstrated that the test has a sensitivity of ≥93% and specificity of 100%. This new and accurate mAb-based multiplexed assay could be a useful resource to diagnose most clinical forms and/or the severity of the disease e.g., active VL, asymptomatic VL, post kala-azar dermal leishmaniasis, VL/HIV co-infection, etc.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R44-AI113992)
This publication has 35 references indexed in Scilit:
- Potential Non-invasive Urine-Based Antigen (Protein) Detection Assay to Diagnose Active Visceral LeishmaniasisPLOS Neglected Tropical Diseases, 2013
- Identification and Diagnostic Utility of Leishmania infantum Proteins Found in Urine Samples from Patients with Visceral LeishmaniasisClinical and Vaccine Immunology, 2012
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- Predictors of Visceral Leishmaniasis Relapse in HIV-Infected Patients: A Systematic ReviewPLOS Neglected Tropical Diseases, 2011
- Diagnosis of Indian Visceral Leishmaniasis by Nucleic Acid Detection Using PCRPLOS ONE, 2011
- Diagnosis of visceral leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2011
- Infectivity of five different types of macrophages by Leishmania infantumActa Tropica, 2007
- Clinical Use of Polymerase Chain Reaction Performed on Peripheral Blood and Bone Marrow Samples for the Diagnosis and Monitoring of Visceral Leishmaniasis in HIV-Infected and HIV-Uninfected Patients: A Single-Center, 8-Year Experience in Italy and Review of the LiteratureClinical Infectious Diseases, 2007
- Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural NepalTropical Medicine & International Health, 2006
- Cloning and Characterization of a Gene Encoding an Immunoglobulin-Binding Receptor on the Cell Surface of Some Members of the FamilyTrypanosomatidaeInfection and Immunity, 2003